https://www.optimumcomms.com/wp-content/uploads/2023/08/Invizius_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-07 08:36:542024-02-07 08:36:54Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-07 08:35:252024-02-07 08:35:25Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-06 08:39:582024-02-07 08:40:10Novo Holdings invests in Manipal Hospitals, a leading private hospital chain in India
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neophare_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-01 08:38:352024-02-01 08:38:35NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-26 13:00:232024-01-26 13:53:42Update on Regulatory Review of leriglitazone in the EU
https://www.optimumcomms.com/wp-content/uploads/2023/06/Breye_Logo_300x180px-80x80-6.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-25 08:39:122024-01-25 08:39:12Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-23 09:33:062024-01-23 09:33:06Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson’s disease
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-23 08:41:062024-02-07 08:43:00Novo Holdings announces pre-IPO investment in Medi Assist, the top health benefits’ administrator in India
https://www.optimumcomms.com/wp-content/uploads/2023/07/SynendosTx_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-18 08:56:142024-01-18 08:56:14Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-17 08:38:172024-01-17 08:38:17Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-17 08:37:422024-01-17 08:37:42AMSilk and 21st.BIO announce partnership to accelerate the production of advanced materials made from spider silk-based proteins
https://www.optimumcomms.com/wp-content/uploads/2024/01/DISCO_Logo_300x180px-80x80-2.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-16 09:11:312024-01-16 09:13:53DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-16 08:34:192024-01-16 08:35:09Biocomposites expands its international presence by opening new sales and distribution office in Italy
https://www.optimumcomms.com/wp-content/uploads/2024/01/DelSiTech_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-16 08:06:072024-01-16 09:14:22DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-15 07:15:322024-01-15 07:15:32Futura Medical extends collaboration with Cooper Consumer Health
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-10 08:44:382024-01-10 08:44:38Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-09 11:48:092024-01-10 16:23:34Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-09 08:52:542024-01-09 08:52:54Futura Medical plc – Appointment of Roy Davis as Non-Executive Director
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-05 14:00:452024-01-09 11:54:33Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-04 08:47:002024-01-04 08:47:002023 Novo Holdings Seed Investments Team Annual Review/Business UpdateFor more information about Optimum Strategic Communications, please get in touch.
